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Background.  The first iteration of the EU Directive that controls the 1 
deliberate release of GMOs into the environment was adopted in 1990, and 2 
the first commercial planting of GM crops occurred in 1996 in the USA (or 3 
1998 in the EU).  Since then, the global cultivated area has risen to exceed 4 
170 M ha and the majority of global production of soya and cotton is via GM 5 
varieties [1].  Over this period, cultivation within the EU has been restricted to 6 
ca 0.1M ha.  Although the main barrier to release of GM food crops for 7 
cultivation in the EU lies at the political level, the UK Advisory Committee on 8 
Releases to the Environment (ACRE) has recently raised concerns both about 9 
the regulatory approach adopted by the EU and the implementation of the 10 
current  current processes for carrying out Environmental Risk assessments 11 
(ERA) process and about their future fitness for purpose (ACRE 12 
http://www.*wp1-3).  This article summarises these concerns and suggests a 13 
way forward. 14 
Addressing current challenges.  These include the lack of precision with 15 
which the concept of adverse effects (harm) is used within ERA and the 16 
challenges of developing a proportionate approach to unanticipated effects  17 
Adverse Effects.  There is no consensus within the EU as to what constitutes an 18 
adverse environmental effect.  This has led to increasing data requirements and 19 
to inappropriate recommendations for risk management options.  The , and this 20 
leads to difficulties asre illustrated by GM herbicide tolerant crops. These 21 
systems allow farmers to practice efficient weed control to enhance crop 22 
productivity, potentially at the expense of biodiversity that depends upon weeds 23 
at the base of the food chain. This negative impact could be compensated for by 24 
Comment [RSH1]: Actually the 
example we give, with GMHT crops, is 
about absence of defined risk management 
because harm has not been defined. This 
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 3 
setting aside field margins or other areas for farmland biodiversity, but in the 1 
absence of clear guidelines on what does or does not constitute harm, 2 
appropriate compensatory measures cannot be usefully defined.  Defining harm 3 
would also facilitate a more structured approach to ERA [2], thus reducing the 4 
inclusion of extraneous information and improving the value of the ERA in 5 
decision-making.  6 
 7 
Monitoring and dDealing with the unexpected. In addition to assessing the risks 8 
associated with the intended changes made to a GM crop, ERA must also 9 
address the possibility that any identified unintended changes could cause 10 
harm.  In the absence of a plausible link between a characteristic of a GM crop 11 
(and its use) and such harm, there is the potential for open-ended evidence-12 
gathering that does not add value to the risk assessment.  It is not possible 13 
practical to test for ERA to identify unintended effects in advance by testing 14 
every characteristic of a GM crop and its use under every conceivable scenario. 15 
It is important therefore, that the EU adopts a proportionate approach that 16 
makes optimal use of existing evidence.  There is a significant 'weight of 17 
evidence’ available from the cultivation of GM crops outside of the EU as well as 18 
from existing information requirements.  Where this evidence indicates changes 19 
to a GM crop, or its use ,are identified and potentially that can be linked to 20 
adverse effects, the ERA should follow a structured and proportionate process 21 
to characterise the risk to the environment. Where identified but unintended 22 
changes cannot be plausibly linked to adverse effects, further data should not 23 
be required. 24 
Comment [RSH2]: I think its important 
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 Finally, some countries, including those in the EU, require post-market 1 
monitoring to detect any unanticipated adverse effects from the commercial 2 
growing of GM crops. In this context, WhereIn terms of unintended effects, 3 
cannot be defined nor linked to a GMO, ACRE supports the use of effective 4 
questionnaires  to detect significant changes aimed at users of the product but 5 
is doubtful of the value of large-scale environmental monitoring to attribute 6 
causality to the cultivation of GM crops 7 
(http://www.defra.gov.uk/acre/files/pmem-final-report.pdf; ACRE http://* WP2). 8 
Emerging Challenges For Process-based Regulation. The current EU 9 
Directive lists techniques that can lead to the generation of GMOs and those 10 
which are deemed not to.  However, these lists are not exhaustive, which leads 11 
to confusion in interpretation of the regulations as to whether the legislation 12 
applies to novel organisms developed by techniques that were not envisaged  13 
when the legislation was adopted in 1990. This approach to regulating 14 
organisms based on how they were produced (so-called “process-based”) was 15 
adopted in 1990 and at this time, many of the techniques being used and 16 
developed today were not envisaged. Consequently, it is not clear whether the 17 
organisms produced by them are captured by the GMO legislation. This results 18 
in regulatory uncertainty – a major block to innovation and to effective ERA.  19 
Adoption of a process-based regulatory system dditionally, basing a regulatory 20 
system on how organisms are produced has resulted in also results in 21 
organisms with the same phenotype being dealt with differently (e.g. 22 
phenotypically identical herbicide-tolerant plants produced by transgenesis or 23 
traditional mutagenesis).  This disparity may increase become more evident 24 
depending on whether regulators consider organisms produced by a suite of 25 
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 5 
new techniques as GMOs.  Regulation of process-based approaches is both 1 
open to interpretation and difficult to future-proof.  PFor example, plants 2 
developed using chemical or radiation mutagenesis are exempt from existing 3 
EU regulation.  However, the same trait in the same organism caused by the 4 
same sequence alteration but using a different mutagenic process (such as zinc 5 
finger nucleases, TALENS or oligonucleotides) may be covered, depending on 6 
the interpretation of the EU Commission and member-state regulators.  7 
Furthermore, Ttheir views are likely to differ as reflected in It is likely that the 8 
conclusions will reflect those set out in the EU Commission’s working group 9 
report on New Technologies [3].  Other emerging technologies involveclude GM  10 
techniques that are captured by the definition of a GMO during the as part of the 11 
breeding process but that result in an organisms that does not contain any 12 
inserted or recombinant DNA (e.g. reverse breeding).  As the process requires 13 
the use of a GM intermediate, some may argue that the resultant organism is 14 
captured by the directive GMO legislation whereas others may considernot.  15 
that it is not because the product could have occurred naturally.   16 
 17 
We conclude that a process-based approach to regulation is difficult to interpret 18 
and to future-proof and this will become more apparent as the technology and 19 
its application advances.problematic now, and likely to become more so in the 20 
future.  This is also consistent with current views of genome organisation that do 21 
not align with the EU definition of a GMO (“an organism...in which the genetic 22 
material has been altered in a way that does not occur naturally by mating 23 
and/or natural recombination.")   When this was written, genomes were 24 
considered to be relatively uniform and stable and the definition was intended to 25 
Comment [m7]: This concept hasn’t 
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 6 
capture the range of artificially induced alterations to an organism’s genetic 1 
material.  Now that the extent of natural genetic and epigenetic variation is more 2 
fully understood, identifying alterations that do not occur naturally is much more 3 
challenging.  Within an individual and between individuals of the same species, 4 
the genetic material can exist in naturally altered forms whilst the phenotype 5 
remains unchanged, through the effects of genetic redundancy between 6 
multigene family members [4,5]  Equally, a single nucleotide change can result 7 
in a significant phenotype change (ACRE http://www.wp3*). 8 
 9 
Options for Change.  A major reason for regulating organisms based on how 10 
they were developed is to address the concern that the technologies may cause 11 
unintended alterations to the organisms’ genetic material that could not have 12 
occurred naturally or through conventional breeding. Since the GMO legislation 13 
was adopted in 1990 we have learned a great deal from genomic studies. We 14 
now understand that this notion that genomes are relatively uniform and stable 15 
entities is incorrect. Within an individual and between individuals of the same 16 
species, the genetic material can exist in naturally altered forms whilst the 17 
phenotype remains unchanged, through the effects of genetic redundancy 18 
between multigene family members [4,5]  Equally, a single nucleotide change 19 
can result in a significant phenotype change (ACRE http://www.wp3*).  We have 20 
also gained  significant evidence from the widespread use of GMOs. From this 21 
we conclude thatWe propose that there is little scientific justification for a 22 
regulatory system that is triggered by the process by which new organisms are 23 
developed (i.e. recombinant DNA technology) rather than by their novelty or 24 
potential for harm (i.e. their phenotype).   25 
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 1 
Additionally, we suggest that a regulatory system that takes account of potential 2 
benefits and includes potential compensatory measures (thus encouraging a 3 
more explicit cost-benefit approach) would better align with other regulatory 4 
frameworks and result in greater potential benefits for the environment and 5 
human health than the existing system.  This approach would also improve the 6 
efficiency of the process to ensure appropriate risk assessment without stifling 7 
innovation.technological  . It and would obviate the pressure to develop need for 8 
technological approaches that are developed purely to deliver material that lies 9 
outside current regulations (ACRE http://www.wp2*).  Shifting to a phenotype-10 
based system would also permit resolution of the wider issues discussed above 11 
and promote proportionate and effective ERA assessments backed by 12 
appropriate post-market surveillance monitoring (ACRE http://www.wp3*).  13 
Further details of such a system are given in (ACRE http://www.wp1*) 14 
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